Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BenevolentAI Bio
Phase 2b study will be conducted with the aim of investigating the efficacy and safety of three fixed doses of Bavisant (0.5, 1 and 3 mg/d) compared to placebo for the treatment of excessive daytime sleepiness (EDS) in subjects with Parkinson's disease.
Age
50–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects of either sex aged 50 to 80 years \*Subjects with previous diagnosis of Parkinson's disease (following the UK Parkinson's disease society brain bank clinical diagnostic criteria)\*
Subjects capable of understanding and complying with protocol requirements
Subjects with medical history of excessive daytime sleepiness
You may not be if
Subjects with excessive daytime sleepiness due to conditions other than Parkinson's disease (including narcolepsy)
Subjects with clinical evidence of depression with significant psychiatric comorbidities (Hamilton Rating Scale for Depression - HAM-D score greater than or equal to 17; with or without treatment)
Subjects with evidence of significant fatigue (Fatigue Severity Scale - FSS greater than or equal to 36
Subjects with known history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.
Subjects with known allergies or hypersensitivity to Bavisant or any of its excipients.
Subjects who are pregnant or lactating.
Clareo Health | BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness
